Neuroimaging Core

神经影像核心

• 批准号: 10663897
• 负责人: JOHN A DETRE
• 金额: $ 67.59万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10663897
• 关键词: Aging; Alzheimer disease detection; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Amyloid; Amyloid beta-Protein; Angiography; Autopsy; Biological; Biological Markers; Blood Vessels; Brain; Brain imaging; Cerebral hemisphere; Clinical; Clinical Research; Collaborations; Consensus; Data; Data Provenance; Databases; Development; Dimensions; Disease; Disease Progression; Doctor of Medicine; Doctor of Philosophy; Evaluation; Functional Imaging; Genetic; Genomics; Heterogeneity; Histopathology; Image; Image Analysis; Incidence; Infrastructure; Institution; Intervention; Link; MRI Scans; Magnetic Resonance Imaging; Maps; Measures; Metadata; Methods; Modality; Molecular; Monitor; Nerve Degeneration; Neurodegenerative Disorders; Optical Coherence Tomography; Participant; Pathology; Phenotype; Plasma; Positron-Emission Tomography; Procedures; Process; Protocols documentation; Reproducibility; Research; Research Personnel; Research Subjects; Resources; Retina; Risk; Sampling; Scanning; Scientist; Slide; Specificity; Staging; Structure; Tissues; Tracer; Training and Education; Translations; Universities; Update; Validation; Washington; biomarker development; brain behavior; brain tissue; clinical center; cohort; data infrastructure; data integration; data management; data sharing; digital; digital pathology; education research; flexibility; image guided; imaging informatics; imaging study; in vivo; informatics infrastructure; insight; ischemic lesion; method development; molecular imaging; morphometry; multimodality; neuroimaging; neuroimaging marker; neuroinflammation; neuropathology; neurovascular; novel; outreach; perfusion imaging; pre-clinical; radioligand; recruit; retinal imaging; statistics; structural imaging; tau Proteins

Neuroimaging Core Project Summary Because of their tolerability, versatility, and spatial specificity, neuroimaging biomarkers are a prominent strategy used in AD/ADRD research to detect AD pathology, provide insights into disease mechanism and heterogeneity, track disease progression and, ultimately, monitor the efficacy of disease-modifying interventions. Neuroimaging methods can also noninvasively assess other neuropathophysiological mechanisms such as neurovascular insufficiency and neuroinflammation that are implicated as mechanisms and modulators of AD and therefore likely contribute to the heterogeneity observed in its risk, incidence, and progression. When linked to postmortem measures of proteinopathy burden, imaging measures can shed light on heterogeneity of AD/ADRD, allowing for discovery of in vivo signatures of “pure AD” and concomitant non- AD pathologies. The Penn ADRC Neuroimaging Core will consolidate expertise in advanced neuroimaging methods and applications to support the acquisition and analysis of state-of-the-art multimodal MRI of brain structure and function, molecular brain imaging using PET, retinal angiography using optical coherence tomography (OCTA). The Neuroimaging Core will oversee the acquisition and analysis of standard MRI and PET scans used in defining preclinical AD based on amyloid, tau, and neurodegeneration (“A/T/(N)”) staging and for quantifying ischemic lesions in the brain. Additional unique features of the Neuroimaging Core include the use of ultra- high-field (7T) MRI both in vivo and for post-mortem imaging of intact hemispheres, the development methods for accurate image-guided sampling of post-mortem brain tissue allowing spatial linkage between digital pathology and in vivo morphometry, the development a data infrastructure linking imaging and non-imaging databases, novel MRI and OCT methods for quantifying brain structure and vascular function in ADRC research, and infrastructure to support the translation of novel PET tracers to clinical research in AD/ADRD. The Neuroimaging Core will also share imaging data collected at the Penn ADRC with the NACC Coordinating Center at the University of Washington and SCAN U24. The Neuroimaging Core will be highly integrated with other ADRC cores, providing access to advanced imaging and derived imaging metrics for the Clinical Core, collaboration on image analysis and databasing of image-based information with the Data Management and Statistics Core, linking in vivo and postmortem neuroimaging to neuropathology in conjunction with the Neuropathology Core, leveraging imaging as a means of linking genetic factors with structural and functional brain phenotype with Genomics Core, working with the Outreach Recruitment and Engagement Core to provide research updates about neuroimaging advances and promote participation in imaging studies, and providing education and training in neuroimaging through Research Education Component.

神经成像核心项目摘要 由于它们的耐受性、多功能性和空间特异性，神经成像生物标记物是一种突出的 AD/ADRD研究中使用的策略，以检测AD病理，提供对疾病机制和 异质性，跟踪疾病进展，并最终监测疾病修改的效果 干预措施。神经成像方法也可以无创地评估其他神经病理生理学 神经血管功能不全和神经炎症等机制被认为是机制 和AD的调节因子，因此可能有助于观察到AD的风险、发病率和 进步。当与蛋白质病负担的死后测量相联系时，成像测量可以揭示 关于AD/ADRD的异质性，允许发现“纯AD”和伴随的非AD的活体特征 广告病理学。 宾夕法尼亚大学ADRC神经成像核心将巩固先进神经成像方法和 支持获取和分析最先进的多模式脑结构和磁共振成像的应用程序 功能，使用PET的分子脑成像，使用光学相干断层扫描(OCTA)的视网膜血管成像。 神经成像核心将监督标准MRI和PET扫描的获取和分析，这些扫描用于 根据淀粉样蛋白、tau蛋白和神经变性(“A/T/(N)”)分期和量化来定义临床前AD 脑内的缺血性损伤。神经成像核心的其他独特功能包括使用超 高场(7T)MRI在活体和死后完整大脑半球成像的发展方法 用于精确的图像引导的死后脑组织采样，允许数字 病理学和活体形态计量学，开发连接成像和非成像的数据基础设施 ADRC中定量脑结构和血管功能的数据库、MRI和OCT新方法 支持将新型PET示踪剂转化为AD/ADRD临床研究的研究和基础设施。 神经成像核心还将与NACC协调中心共享在宾夕法尼亚大学ADRC收集的成像数据 在华盛顿大学中心，扫描U24。 神经成像核心将与其他ADRC核心高度集成，提供访问高级 临床核心的成像和派生成像指标，图像分析和数据库方面的协作 以图像为基础的信息，以数据管理和统计为核心，将活体和死后联系起来 结合神经病理学核心的神经成像到神经病理学，利用成像作为一种手段 将遗传因素与大脑结构和功能表型与基因组学核心联系起来，与 外展招聘和参与核心，提供有关神经成像进展和 促进参与成像研究，并通过以下方式提供神经成像方面的教育和培训 研究教育部分。